English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Self-amplifying RNAs (replicons) of positive-strand viruses are useful vectors for delivering vaccine antigens. Novartis has developed a self-amplifying mRNA (SAMTM) vaccine platform to take advantage of cell-free RNA production and synthetic non-viral delivery systems. In this study, the safety, immunogenicity, and efficacy of HIV-SAMTM vaccines encoding HIV-1 clade C TV1 gp140 envelope glycoprotein were evaluated in rhesus macaques using two non-viral delivery systems: lipid nanoparticle (LNP) and a Novartis proprietary 2nd generation delivery technology (CNE).

Macaques primed with self-amplifying RNA vaccines expressing HIV-1 envelope and boosted with recombinant protein show potent T- and B-cell responses